ITRM
Iterum Therapeutics plc [ITRM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ITRM Stock Summary
Top 10 Correlated ETFs
ITRM
Top 10 Correlated Stocks
ITRM
In the News
ITRM Financial details
Company Rating
-
Market Cap
21.2M
Income
-38.37M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.91
Forward P/E
-
PEG
0.5
P/S
-
P/B
8.28
P/C
-
P/FCF
-0.95
Quick Ratio
2.2
Current Ratio
2.35
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.97
EPS next Y
-
EPS next Q
-
EPS this Y
-18.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.05%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
213.33%
-
-
-
-
SMA20
-22.41%
SMA50
-35.71%
SMA100
-50.55%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
-216%
ROC
-1.88%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.622-2.5
52W High
-
52W Low
-
RSI
43.13
Rel Volume
0.86
Avg Volume
630.86K
Volume
543.51K
Perf Week
7.86%
Perf Month
-30.65%
Perf Quarter
-54.25%
Perf Half Y
-56.73%
-
-
-
-
Beta
2.363
-
-
Volatility
0.01%, 0.09%
Prev Close
-4.13%
Price
0.45
Change
-2.17%
Company Profile
- Volume Average 630.86K
- Market Capitalization 21.2M
- Employee 14
- CEO Mr. Corey N. Fishman
- Headquarters Dublin,IE
- IPO Date 2018-05-25
-
Website
https://www.iterumtx.com 
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
